medigraphic.com
ISSN 1405-1710 (Print)

2019, Number 1

Next >>

Rev Cent Dermatol Pascua 2019; 28 (1)

Dermatological use of the Potential Repigmentation Index (PRI) for the prognosis of adults with incipient non-segmental vitiligo

De la Torre-García ME, Peralta-Pedrero ML, Morales-Sánchez MA, Jurado-Santa Cruz F, Cruz-Avelar A

Language: Spanish
References: 21
Page: 5-10
PDF size: 196.99 Kb.


ABSTRACT

Background: Vitiligo is an acquired dyschromia, resulting from the destruction of melanocytes, clinically expressed as acromic spots on skin, hair and mucous membranes, well defined and asymptomatic. The Potential Repigmentation Index aims to predict the likelihood of repigmentation in response to treatment. Methodology: In the Centro Dermatológico Dr. Ladislao de la Pascua in Mexico City, from January to December 2017 in a cross-sectional study, adults with non-segmental vitiligo were included, ≤ 24 months of evolution. We excluded patients with non-segmental vitiligo mixed subtype, universal vitiligo and vitiligoid conditions as a result of depigmenting treatments. Affected body surface was determined. Results: 40 patients with non-segmental vitiligo, age 40 ± 11.9 years. Minimum affected body surface was 0.01% and maximum of 12.91%. Number of injuries from 1 to 154. The Potential Repigmentation Index could be applied to 20% of the sample, resulting in a minimum score of 0.5 and a maximum score of 11.5 at a higher score, better prognosis for the response to treatment in terms of repigmentation. Conclusions: It is important to obtain an overall rating of the patient in terms of prognosis of the response to treatment, the Potential Repigmentation Index has problems of content validity and is not susceptible to be used in the majority of patients with incipient non-segmental vitiligo.


REFERENCES

  1. Rodríguez-Cerdeira C, Arenas Guzmán R. El vitíligo, una enfermedad estigmática: un recorrido a través de su historia. Med Cutan Ibero Lat Am. 2011; 39: 278-282.

  2. Khaitan BK, Kathuria S, Ramam M. A descriptive study to characterize segmental vitiligo. Indian J Dermatology Venereol Leprol. 2012; 78: 715-721.

  3. Ortega RA, Garcia RM, Lacy NR. El vitiligo y su repigmentación. Dermatologia CMQ. 2009; 7: 270-279.

  4. Benzekri L, Ezzedine K, Gauthier Y. Vitiligo potential repigmentation index: a simple clinical score that might predict the ability of vitiligo lesions to repigment under therapy. B J Dermatol. 2013; 168: 1143-1146.

  5. Van Geel N, Lommerts J, Bekkenk M, Wolkerstorfer A, Prinsen CAC, Eleftheriadou V et al. Development and validation of the vitiligo extent score (VES): an International Collaborative Initiative. J Invest Dermatol. 2016; 136: 978-984.

  6. González U, Whitton M, Eleftheriadou V, Pinart M, Batchelor J, Leonardi-Bee J. Guidelines for designing and reporting clinical trials in vitiligo. Arch Dermatol. 2011; 147: 1428-1436.

  7. Eleftheriadou V, Whitton ME, Gawkrodger DJ, Batchelor JM, Corne J, Lamb B et al. Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership. Br J Dermatol. 2011; 164: 530-536.

  8. Eleftheriadou V. Future Horizons in vitiligo research: focusing on the recommendations of the Cochrane systematic review “Interventions for vitiligo” 2010. Br J Dermatol. 2013; 169: 67-70. Available from: http://mcb.asm.org/cgi/doi/10.1128/MCB.01195-12.

  9. Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012; 25: E1-13.

  10. Whitton ME, Pinart M, Batchelor J, Leonardi-Bee J, González U, Jiyad Z et al. Interventions for vitiligo. Cochrane Database Syst Rev. 2015 (2): CD003263.

  11. Anbar T, Abdel-Rahman A, Hegazy R, El-Khayyat M, Ragaie M. Simultaneous improvement and worsening of vitiligo lesions during the course of NB-UVB phototherapy; vitiligo may not act as one unit. Dermatol Ther. 2017; 30: 1-6.

  12. Eleftheriadou V, Thomas KS, Whitton ME, Batchelor JM, Ravenscroft JC. Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials. Br J Dermatol. 2012; 167: 804-814.

  13. Tour SK, Thomas KS, Walker DM, Leighton P, Yong ASW, Batchelor JM. Survey and online discussion groups to develop a patient-rated outcome measure on acceptability of treatment response in vitiligo. BMC Dermatol. 2014; 14: 1-12.

  14. van Geel N, Bekkenk M, Lommerts JE, Ezzedine K, Harris J, Hamzavi I et al. The Vitiligo Extent Score (VES) and the VESplus are responsive instruments to assess global and regional treatment response in patients with vitiligo. J Am Acad Dermatol. 2018; 79: 369-371. Available from: https://doi.org/10.1016/j.jaad.2017.12.070

  15. Gottlieb AB, Levin AA, Armstrong AW, Abernethy A, Duffin KC, Bhushan R et al. The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology. J Am Dermatology. 2015; 72: 345-348. Available from: http://dx.doi.org/10.1016/j.jaad.2014.11.002

  16. Peralta-Pedrero ML, Jurado Santa-Cruz F. Experiencia de un investigador y un dermatólogo sobre el conocimiento del curso clínico del vitiligo no segmentario. Actas Dermosifiliogr. 2018; 109: 767-770. https://doi.org/10.1016/j.ad.2018.05.008

  17. Esmat SM, El-Tawdy AM, Hafez GA, Zeid OA, Abdel Halim DM, Saleh MA et al. Acral lesions of vitiligo: Why are they resistant to photochemotherapy? J Eur Acad Dermatol Venereol. 2012; 26: 1097-1104.

  18. Silva de Castro CC, do Nascimento LM, Olandoski M, Mira MT. A pattern of association between clinical form of vitiligo and disease-related variables in a Brazilian population. J Dermatol Sci. 2012; 65: 63-67.

  19. Liu JB, Li M, Yang S, Gui JP, Wang HY, Du WH et al. Clinical profiles of vitiligo in China: An analysis of 3742 patients. Clin Exp Dermatol. 2005; 30: 327-331.

  20. Sharma YK, Bansal P, Menon S, Prakash N. Metabolic syndrome in vitiligo patients among a semi-urban Maharashtrian population: a case control study. Diabetes Metab Syndr. 2017; 11: S77-S80. Available from: https://doi.org/10.1016/j.dsx.2016.12.009

  21. Gill L, Zarbo A, Isedeh P, Jacobsen G, Lim HW, Hamzavi I. Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study. J Am Acad Dermatol. 2016; 74: 295-302. Available from: http://dx.doi.org/10.1016/j.jaad.2015.08.063




2020     |     www.medigraphic.com